01-10-2019 | Prostate Cancer | PHASE I STUDIES
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer
Published in: Investigational New Drugs | Issue 5/2019
Login to get access